Skip to main content
. 2013 Jun;57(6):2526–2534. doi: 10.1128/AAC.00197-13

Table 1.

Demographic and baseline characteristics

Characteristic [statistic]a ITT population
CE population
Solithromycin 800/400 mg (N = 65) Levofloxacin 750 mg (N = 67) Solithromycin 800/400 mg (N = 55) Levofloxacin 750 mg (N = 58)
Patients in each country [n (%)]
    United States 63 (96.9) 63 (94.0) 54 (98.2) 54 (93.1)
    Canada 2 (3.1) 4 (6.0) 1 (1.8) 4 (6.9)
Age (yr)
    Mean ± SD 56.0 ± 13.0 55.2 ± 14.1 56.5 ± 13.2 54.8 ± 14.4
    Range 25–87 18–79 25–87 18–79
    ≥65 [n (%)] 19 (29.2) 17 (25.4) 16 (29.1) 15 (25.9)
Race [n (%)]
    White 55 (84.6) 54 (80.6) 45 (81.8) 46 (79.3)
    Asian 5 (7.7) 6 (9.0) 5 (9.1) 5 (8.6)
    Black 3 (4.6) 6 (9.0) 3 (5.5) 6 (10.3)
    American Indian or Alaskan Native 1 (1.5) 0 (0.0) 1 (1.8) 0 (0.0)
    Native Hawaiian/other Pacific Islander 1 (1.5) 0 (0.0) 1 (1.8) 0 (0.0)
    Other 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.7)
Ethnicity [n (%)]
    Non-Hispanic or Latino 54 (83.1) 56 (83.6) 46 (83.6) 48 (82.8)
    Hispanic or Latino 11 (16.9) 11 (16.4) 9 (16.4) 10 (17.2)
Gender [n (%)]
    Male 28 (43.1) 39 (58.2) 25 (45.5) 34 (58.6)
    Female 37 (56.9) 28 (41.8) 30 (54.5) 24 (41.4)
BMIb (kg/m2)
    Mean ± SD 30.4 ± 7.5 28.6 ± 6.6 30.5 ± 7.3 27.9 ± 6.1
    Range 14.1, 64.5 15.5, 52.6 14.1, 64.5 15.5, 46.2
PORT score risk class [n (%)]
    I (0–50) 2 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
    II (51–70) 47 (72.3) 50 (74.6) 39 (70.9) 44 (75.9)
    III (71–90) 12 (18.5) 15 (22.4) 12 (21.8) 13 (22.4)
    IV (91–105) (IVa + IVb) 4 (6.2) 2 (3.0) 4 (7.3) 1 (1.7)
    IVa (91–98) 3 (4.6) 1 (1.5) 3 (5.5) 0 (0.0)
    IVb (99–105) 1 (1.5) 1 (1.5) 1 (1.8) 1 (1.7)
Enrolled as a prior treatment failure [n (%)] 6 (9.2) 4 (6.0) 6 (10.9) 4 (6.9)
a

n, number of patients with characteristic; N, number of patients in the specified population; %, 100 × (n/N).

b

BMI, body mass index.

HHS Vulnerability Disclosure